Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Align Technology, Inc.
Align Technology makes clear dental braces and the scanning tools dentists use to plan and deliver them.
Align Technology makes the clear plastic aligners that straighten teeth without metal braces. Its main brand is Invisalign: a series of custom, removable trays that slowly move teeth into place. Most people know the company through that product, and it sells to dentists and orthodontists, who in turn sell treatment to patients. Alongside the aligners, it makes iTero intraoral scanners — the handheld wands that take a fast 3D digital model of your mouth — and exocad software that dental labs and clinics use to design restorations.
The business works like a razor-and-blades model in reverse: the scanner and software pull dentists into Align's digital world, and the aligners are the high-value product that gets ordered again and again. Customers choose Invisalign because it is the best-known clear-aligner brand, backed by decades of clinical data, a huge case library, and a steady flow of new features like faster treatment plans and smart tracking. The catch is that the moat is not unbreakable. Rival clear-aligner makers, including Dentsply Sirona, sell cheaper alternatives, and Align's growth depends heavily on convincing more general dentists — not just orthodontists — to offer aligners, plus expanding in overseas markets like China and Europe. The company is headquartered in Tempe, Arizona, and it has invested heavily in its own manufacturing, building out plants and digital printing capacity so it can turn around custom aligners quickly. That vertical integration supports its margins but also makes it a capital-hungry business at times. Its scanner and software segment has grown into a meaningful second leg, especially as iTero scanners become a common fixture in dental offices and help feed the aligner funnel.
The clearest recent story is the teen and young-adult market, where Align has pushed Invisalign hard, and the broader push to make clear aligners the default choice for mild-to-moderate cases. It also faces a competitive threat from low-cost direct-to-consumer aligner startups that skip the dentist — a model Align has largely avoided, betting instead that professional oversight is the safer, stickier path. Growth has cooled from its pandemic-era boom, and investors watch case volumes and average selling prices closely, since price cuts to win share can dent the premium image the brand has built.
Saved answer · last researched 15 Nov 2026